Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype-Reference-Cited by-同舟云学术

Early Stage HER2-Positive Breast Cancers Not Achieving a pCR From Neoadjuvant Trastuzumab- or Pertuzumab-Based Regimens Have an Immunosuppressive Phenotype

Published:2018-10 Issue:5 Volume:18 Page:410-417
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Force Jeremy,Howie Lynn J.,Abbott Sara E.,Bentley Rex,Marcom P. Kelly,Kimmick Gretchen,Westbrook Kelly,Sammons Sarah L.,Parks Michelle,Topping Donna L.,Emerson Ryan,Broadwater Gloria,Hyslop Terry,Blackwell Kimberly L.,Nair Smita K.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference39 articles.

1. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen;Schechter;Nature,1984

2. Amplification of a novel v-erbB-related gene in a human mammary carcinoma;King;Science,1985

3. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer;Wright;Cancer Res,1989

4. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;Slamon;Science,1987

5. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831;Perez;J Clin Oncol,2014

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review concerning the breast cancer-related tumour microenvironment;Critical Reviews in Oncology/Hematology;2024-07

2. HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial;Journal of Clinical Investigation;2024-02-01

3. The association of PD-L1 expression and CD8-positive T cell infiltration rate with the pathological complete response after neoadjuvant treatment in HER2-positive breast cancer;Breast Cancer Research and Treatment;2024-01-25

4. Resistance of HER2-expressing ovarian cancer to trastuzumab and mechanisms of overcoming resistance;Overcoming Cancers Resistant to HER-2 Antibodies;2024

5. A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer;Clinical Cancer Research;2023-07-07